The estimated Net Worth of Rafael Bejar is at least $570 Thousand dollars as of 19 November 2021. Dr Bejar owns over 10,000 units of Aptose Biosciences Inc stock worth over $3,500 and over the last 5 years he sold APTO stock worth over $0. In addition, he makes $566,923 as Sr. VP & Chief Medical Officer at Aptose Biosciences Inc.
Dr has made over 1 trades of the Aptose Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of APTO stock worth $25,600 on 19 November 2021.
The largest trade he's ever made was buying 10,000 units of Aptose Biosciences Inc stock on 19 November 2021 worth over $25,600. On average, Dr trades about 1,250 units every 0 days since 2020. As of 19 November 2021 he still owns at least 10,000 units of Aptose Biosciences Inc stock.
You can see the complete history of Dr Bejar stock trades at the bottom of the page.
Dr. Rafael Bejar M.D., Ph.D. is the Sr. VP & Chief Medical Officer at Aptose Biosciences Inc.
As the Sr. VP & Chief Medical Officer of Aptose Biosciences Inc, the total compensation of Dr D at Aptose Biosciences Inc is $566,923. There are 5 executives at Aptose Biosciences Inc getting paid more, with William Rice having the highest compensation of $1,511,900.
Dr D is 49, he's been the Sr. VP & Chief Medical Officer of Aptose Biosciences Inc since . There are 8 older and 4 younger executives at Aptose Biosciences Inc. The oldest executive at Aptose Biosciences Inc is Denis Burger, 75, who is the Lead Independent Director.
Rafael's mailing address filed with the SEC is C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO, A6, M2J 4R3.
Over the last 6 years, insiders at Aptose Biosciences Inc have traded over $2,827,381 worth of Aptose Biosciences Inc stock and bought 538,629 units worth $767,189 . The most active insiders traders include Erich Platzer, Bernd R. Seizinger, and William G. Rice. On average, Aptose Biosciences Inc executives and independent directors trade stock every 59 days with the average trade being worth of $14,277. The most recent stock trade was executed by Bernd R. Seizinger on 22 September 2023, trading 17,000 units of APTO stock currently worth $53,380.
aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
Aptose Biosciences Inc executives and other stock owners filed with the SEC include: